CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events
Authors:
- Michael V. HolmesMHMichael V. Holmes
- Pablo PerelPPPablo Perel
- Tina ShahTSTina Shah
- Aroon D. HingoraniAHAroon D. Hingorani
- Juan P. CasasJCJuan P. Casas
Top Cited Papers
Open Access
- 28 December 2011
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 306 (24) , 2704-2714
Abstract
Review from JAMA — CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events — A Systematic Review and Meta-analysisKeywords
This publication has 45 references indexed in Scilit:
- Large-scale association analysis identifies 13 new susceptibility loci for coronary artery diseaseNature Genetics, 2011
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentNew England Journal of Medicine, 2010
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Genome-wide association study of blood pressure and hypertensionNature Genetics, 2009
- Genome-wide association study identifies eight loci associated with blood pressureNature Genetics, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsNew England Journal of Medicine, 2009
- Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort studyThe Lancet, 2009
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006